[go: up one dir, main page]

PL2672957T3 - Nowe kompozycje do leczenia mukowiscydozy - Google Patents

Nowe kompozycje do leczenia mukowiscydozy

Info

Publication number
PL2672957T3
PL2672957T3 PL12704027T PL12704027T PL2672957T3 PL 2672957 T3 PL2672957 T3 PL 2672957T3 PL 12704027 T PL12704027 T PL 12704027T PL 12704027 T PL12704027 T PL 12704027T PL 2672957 T3 PL2672957 T3 PL 2672957T3
Authority
PL
Poland
Prior art keywords
treatment
cystic fibrosis
novel composition
novel
composition
Prior art date
Application number
PL12704027T
Other languages
English (en)
Inventor
Michael Freissmuth
Christina Gloeckel
Xaver Koenig
Simon Keuerleber
Original Assignee
Scipharm Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2672957(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scipharm Sàrl filed Critical Scipharm Sàrl
Publication of PL2672957T3 publication Critical patent/PL2672957T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12704027T 2011-02-07 2012-02-03 Nowe kompozycje do leczenia mukowiscydozy PL2672957T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11153541 2011-02-07
EP12704027.7A EP2672957B1 (en) 2011-02-07 2012-02-03 Novel composition for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
PL2672957T3 true PL2672957T3 (pl) 2017-05-31

Family

ID=43799687

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12704027T PL2672957T3 (pl) 2011-02-07 2012-02-03 Nowe kompozycje do leczenia mukowiscydozy

Country Status (27)

Country Link
US (1) US9504663B2 (pl)
EP (1) EP2672957B1 (pl)
JP (2) JP5997182B2 (pl)
KR (1) KR101852222B1 (pl)
CN (1) CN103391766B (pl)
AU (1) AU2012215606B2 (pl)
BR (1) BR112013019335B1 (pl)
CA (1) CA2826183C (pl)
CL (1) CL2013002234A1 (pl)
CY (1) CY1119999T1 (pl)
DK (1) DK2672957T3 (pl)
EA (1) EA029760B1 (pl)
ES (1) ES2612510T3 (pl)
HR (1) HRP20170113T1 (pl)
HU (1) HUE031652T2 (pl)
IL (1) IL227738B (pl)
LT (1) LT2672957T (pl)
ME (1) ME02598B (pl)
PL (1) PL2672957T3 (pl)
PT (1) PT2672957T (pl)
RS (1) RS55624B1 (pl)
SG (1) SG192677A1 (pl)
SI (1) SI2672957T1 (pl)
SM (2) SMT201700099T1 (pl)
UA (1) UA113161C2 (pl)
WO (1) WO2012107363A1 (pl)
ZA (1) ZA201305276B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JP7216719B2 (ja) 2017-09-20 2023-02-01 ユニオン・セラピューティクス・アクティエセルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
CN111727191B (zh) * 2017-12-15 2024-01-05 联合疗法公司 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
EP3946351A4 (en) * 2019-03-24 2023-01-04 Aribio Co., Ltd. COMPOSITIONS AND METHODS FOR REDUCING BETA-AMYLOID PROTEIN FORMATION AND COMPOSITION THEREFOR
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物
CA3202852A1 (en) * 2020-12-01 2022-06-09 Reverspah Llc Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension
EP4284366A1 (en) * 2021-01-29 2023-12-06 MediciNova, Inc. Methods of treating chemical gas exposure

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732406B2 (en) 1997-10-03 2001-04-26 Merck Frosst Canada & Co. Aryl thiophene derivatives as PDE IV inhibitors
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
WO2000002450A1 (en) * 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
KR20040008162A (ko) 2001-04-25 2004-01-28 알타나 파마 아게 신규한 프탈라지논
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI347845B (en) 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
CN101090714A (zh) * 2004-07-26 2007-12-19 康泽里克斯公司 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8084221B2 (en) * 2006-04-01 2011-12-27 Saint Louis University Method of screening for a drug candidate that increases ATP release from RBCs stimulated via the Gs or Gi pathway
FR2903693B1 (fr) 2006-07-17 2012-03-30 Inst Nat Polytech Grenoble Sulfinates et halogenures de sulfonyle aromatiques, et leur preparation.
JP2010513533A (ja) * 2006-12-21 2010-04-30 コンサート ファーマシューティカルズ インコーポレイテッド プロスタサイクリン誘導体
US20090325976A1 (en) * 2006-12-21 2009-12-31 Concert Pharmaceuticals Inc. Prostacyclin derivatives
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
AU2010224485B2 (en) * 2009-03-20 2014-04-17 Hg&H Pharmaceuticals (Pty) Ltd Use of pharmaceutical compositions containing mesembrenone
HRP20140277T1 (hr) * 2009-08-07 2014-04-25 Scipharm Sàrl Kompozicija za lijeäśenje cistiäśne fibroze
EP2338520A1 (de) * 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung

Also Published As

Publication number Publication date
CN103391766A (zh) 2013-11-13
ZA201305276B (en) 2014-09-25
SG192677A1 (en) 2013-09-30
CA2826183C (en) 2019-05-14
CN103391766B (zh) 2018-05-25
ES2612510T3 (es) 2017-05-17
JP2014505082A (ja) 2014-02-27
HUE031652T2 (en) 2017-07-28
CA2826183A1 (en) 2012-08-16
BR112013019335B1 (pt) 2022-05-31
SMT201700099B (it) 2017-03-08
IL227738B (en) 2019-05-30
AU2012215606A1 (en) 2013-08-01
CL2013002234A1 (es) 2014-01-03
KR20140007865A (ko) 2014-01-20
UA113161C2 (xx) 2016-12-26
SMT201700099T1 (it) 2017-03-08
HRP20170113T1 (hr) 2017-03-24
BR112013019335A2 (pt) 2020-10-27
JP2016199574A (ja) 2016-12-01
ME02598B (me) 2017-06-20
EP2672957A1 (en) 2013-12-18
SI2672957T1 (sl) 2017-03-31
JP5997182B2 (ja) 2016-09-28
US9504663B2 (en) 2016-11-29
CY1119999T1 (el) 2018-12-12
EA029760B1 (ru) 2018-05-31
WO2012107363A1 (en) 2012-08-16
LT2672957T (lt) 2017-02-10
EP2672957B1 (en) 2016-11-02
DK2672957T3 (da) 2017-02-06
IL227738A0 (en) 2013-09-30
EA201300892A1 (ru) 2013-12-30
AU2012215606B2 (en) 2016-12-22
US20140018430A1 (en) 2014-01-16
PT2672957T (pt) 2017-01-31
RS55624B1 (sr) 2017-06-30
NZ613118A (en) 2015-06-26
KR101852222B1 (ko) 2018-04-25

Similar Documents

Publication Publication Date Title
ZA201305276B (en) Novel composition for the treatment of cystic fibrosis
ZA201404121B (en) Compositions for the treatment of dry eye
IL217899A0 (en) Composition for the treatment of cystic fibrosis
ZA201403795B (en) Formulations for the treatment of diabetes
IL232251A0 (en) Protocol for the treatment of type 2 diabetes
IL228541A0 (en) Compounds for the treatment of neurological disorders
GB201118704D0 (en) Cystic fibrosis treatment
EP2704712A4 (en) ISOXAZOLINES AS THERAPEUTIC AGENTS
ZA201305939B (en) Hair treatment composition
PL2651251T3 (pl) Kompozycja do leczenia bezpłodności
PH12013501623A1 (en) Hair treatment compositions
ZA201401847B (en) Cleansing composition
GB201000499D0 (en) Treatment of cystic fibrosis
ZA201307828B (en) Hard surface treatment composition
GB201117252D0 (en) Improved treatment of hard surfaces
GB201000571D0 (en) Treatment of cystic fibrosis
AU2012900572A0 (en) Compositions and methods for the treatment of cystic fibrosis
IL232294B (en) Preparations for the treatment of diabetes
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
ZA201307836B (en) Hard surface treatment composition
HK1194690A (en) Isoxazolines as therapeutic agents